Skip to NavigationSkip to content

Gilead inks deal with Canadian antibody discovery firm AbCellera

Published on 14/06/19 at 10:50am

Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.

The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.

Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.

Using a sutie of proprietary technologies, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches